



## Fund Summary

▶ <b>Fund Type</b>	Foreign Investment Fund
▶ <b>Fund Registration date</b>	20 August 2021
▶ <b>Investment Policy</b>	The Fund will invest in the investment unit of at least 2 foreign mutual funds that focus on investing in securities/instruments of companies related to the Genomic Revolution Theme, which focuses on and expected to benefit from quality development of human life through development and progress in technology and science, on average, in an accounting year of not less than 80% of the Fund's NAV.
▶ <b>Net Asset Value</b>	Baht 19.32 million
▶ <b>Net Asset Value Per Unit</b>	Baht 2.4011
▶ <b>Policy on Dividend Payment</b>	Pay out no more than 12 times per year
▶ <b>Automatic redemption policy</b>	No AutoRedeem
▶ <b>Risk Involved</b>	<ol style="list-style-type: none"> <li>1. Leverage Risk</li> <li>2. The risk of changes in the price or value of the underlying asset.</li> <li>3. Call Risk</li> <li>4. Liquidity Risk</li> <li>5. Business Risk</li> <li>6. Country Risk</li> <li>7. Repatriation Risk</li> <li>8. Market Risk</li> <li>9. Credit Risk</li> <li>10. Exchange rate Risk</li> <li>11. Reinvestment Risk</li> <li>12. The risk of delay payment from foreign funds.</li> </ol>
▶ <b>FX hedging policy</b>	Discretionary hedged
▶ <b>AIMC Category</b>	Health Care

## Subscription / Redemption

▶ <b>Date &amp; Time</b>	Before 3.30 p.m. of every working day and before 4.00 p.m. for SCB Easy
▶ <b>Minimum Additional Subscription Amount</b>	Baht 1,000 / Baht 1,000
▶ <b>Minimum Redemption</b>	Baht 0
▶ <b>Minimum Balance</b>	Baht 0
▶ <b>Redemption Settlement Date</b>	4 business days after the date of redemption (T+4)


## Fees Collected from Unit holders

▶ <b>Front-end fee</b>	Not exceed 3.21% of NAV (waived)
▶ <b>Back-end fee</b>	Not exceed 3.21% of NAV (waived)
▶ <b>Switch In fee</b>	Not exceed 3.21% of NAV (waived)
▶ <b>Switch Out fee</b>	Not exceed 3.21% of NAV (waived)
▶ <b>Brokerage Fee (All Transaction)</b>	Not exceed 0.75 % of NAV (waived)
▶ <b>Transfer fee</b>	Baht 10 per 1,000 units

## Fees Collected from the Fund (included of VAT)(%p.a.of NAV)

▶ <b>Management Fee</b>	Not exceed 2.68 p.a. (Currently charged at 0.5%)
▶ <b>Trustee Fee</b>	Not exceed 0.11 p.a. (Currently charged at 0.0321%)
▶ <b>Registrar Fee</b>	Not exceed 0.11 p.a. (Currently charged at 0.06527%)
▶ <b>Other expenses</b>	Actual expense Not exceed 2.68%

## Asset Allocation



## Fund Performance vs Benchmark

Fund Performance	Return			Annualized Return				
	YTD	3 Mths	6 Mths	1 Yr	3 Yrs	5 Yrs	10 Yrs	Since Inception
SCBGENOME(SSF)	-12.69%	-15.38%	-20.73%	-18.93%	-16.36%	n.a.	n.a.	-31.43%
Benchmark <sup>1</sup>	2.30%	-0.07%	-6.99%	-5.95%	-8.18%	n.a.	n.a.	-26.12%
Portfolio SD	29.07%	24.18%	30.64%	39.55%	42.59%	n.a.	n.a.	44.95%
Benchmark SD	13.48%	12.65%	16.24%	27.64%	38.58%	n.a.	n.a.	42.11%

Annual Return	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
SCBGENOME(SSF)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-22.03%	-54.51%	6.04%	-26.89%
Benchmark <sup>1</sup>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-21.35%	-54.13%	10.36%	-21.85%
Portfolio SD	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	39.97%	59.51%	36.91%	36.10%
Benchmark SD	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	40.19%	59.90%	35.68%	32.95%

Class Date 20 August 2021

## Fund Details

	% Of NAV
<b>Security</b>	
1.ARK GENOMIC REVOLUTION ETF	72.77
2.ISHARES GENOMICS IMMUNOLOGY AND HEALTHCARE ETF	24.76
3.FORWARD	1.18
<b>Industry</b>	
1.UNIT TRUST	97.53

## Master Fund

SCB Genomic Revolution (Super Savings Fund) -- Master Fund Fact Sheet

## AIMC Category Performance Report

AIMC Category	Average Trailing Return (%)							Average Calendar Year Return (%)				
	YTD	3M	6M	1Y	3Y	5Y	10Y	2020	2021	2022	2023	2024
Health Care	-6.61	-11.33	-13.48	-13.88	-4.98	-0.11	1.41	22.59	7.71	-19.54	-0.96	-7.28

## Remark

<sup>1</sup> Bloomberg Developed Markets Large & Mid Cap Net Return Index (USD) 100% adjusted with the FX hedging cost to calculate return into Thai Baht on investment date (60%) and adjusted with the exchange rate to compare with Thai Baht on return calculation date (40%) (Change of benchmark is effective from 1 April 2025 onwards.)